Oncopeptides ABFRA:OND -1.39%30 Quick Ratio is 4.38 as of Mar. 2026, which is 3% above its 10-year median of 4.25. GuruFocus rates FRA:OND with a GF Score™ of 30/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Oncopeptides AB ranks better than 55.79% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Oncopeptides AB's quick ratio for the quarter that ended in Mar. 2026 was 4.38.
Oncopeptides AB has a quick ratio of 4.38. It generally indicates good short-term financial strength.
The historical rank and industry rank for Oncopeptides AB's Quick Ratio or its related term are showing as below:
FRA:OND'
s Quick Ratio Range Over the Past 10 Years
Min: 1.45 Med: 4.25 Max: 10.53
Current: 4.38
During the past 12 years, Oncopeptides AB's highest Quick Ratio was 10.53. The lowest was 1.45. And the median was 4.25.
FRA:OND's Quick Ratio is ranked better than 55.79% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:OND: 4.38
Oncopeptides AB (FRA:OND) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Oncopeptides AB Quick Ratio Related Terms
Oncopeptides AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OND vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Oncopeptides AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Oncopeptides AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (FRA:OND) has a Quick Ratio of 4.38 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Oncopeptides AB and its competitors. This is near median its historical median of 4.25. Over the past decade, Oncopeptides AB's Quick Ratio has ranged from 1.45 to 10.53. According to the industry distribution chart, Oncopeptides AB ranks #626 out of 1416 companies in the Biotechnology industry, placing it in the top 44.2%.
Is Oncopeptides AB's Quick Ratio too high?
Oncopeptides AB's current Quick Ratio of 4.38 is near median its 10-year median of 4.25. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 10.53. The Biotechnology industry median Quick Ratio is 3.60. Oncopeptides AB's value of 4.38 is 21.7% above this industry median. Based on the distribution chart, Oncopeptides AB ranks #626 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #626 out of 1416 companies for Quick Ratio. This puts Oncopeptides AB in the upper half of its industry. The industry median Quick Ratio is 3.60. Oncopeptides AB's value of 4.38 is 21.7% above this benchmark. Historically, Oncopeptides AB's own Quick Ratio has ranged from 1.45 to 10.53 over the past decade. While the company's 10-year median is 4.25 vs. the industry median of 3.60, Oncopeptides AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncopeptides AB's current Quick Ratio of 4.38 is 21.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current Quick Ratio is 4.38, which is near median its own 10-year median of 4.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.14 — trading 61.6% below its estimated fair value. The current Quick Ratio is 4.38, which is near median its 10-year median of 4.25 and 21.7% above the Biotechnology industry median of 3.60. Oncopeptides AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Quick Ratio is 4.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 61.6% below its estimated GF Value™ of €0.37.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
Quick Ratio: 4.38 (near median its 10-year median of 4.25)
GF Value™: €0.37 vs. price of €0.14 (61.6% below fair value)
Industry Position: 21.7% above the Biotechnology median (#626 of 1416)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
30GF Score
Get the complete analysis for FRA:OND
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
